<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357460</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol D2.0 - 31.08.2010</org_study_id>
    <nct_id>NCT01357460</nct_id>
  </id_info>
  <brief_title>Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency</brief_title>
  <official_title>Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      Patients with advanced heterogeneous emphysema due to alpha1 antitrypsin deficiency might
      benefit from endoscopic implantation of intrabronchial valves.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient enrollment and data acquisition is to be carried out on a prospective basis. It is
      planned to enroll a total of 25 patients with advanced heterogeneous emphysema due to alpha1
      antitrypsin deficiency. All patients will undergo treatment at one study centre in
      Heidelberg. Therapy of all patients consists of implantation of intrabronchial valves (IBV,
      Spiration, Olympus) in the most emphysematous destroyed lobe.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in pulmonary function (FEV1 (forced expiratory volume in 1 second) and RV/TLC (residual volume/total lung capacity)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of major complications</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of IBV migration rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average changes in pulmonary function (FEV1, VC (vital capacity), RV, TLC, RV/TLC)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average changes in 6-minute-walk-distance</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hereditary Emphysema (Alpha 1-antitrypsin Deficiency)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of intrabronchial valves (IBV) (Spiration IBV)</intervention_name>
    <description>In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of &quot;new&quot; air during inspiration.</description>
    <other_name>Spiration IBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pulmonary function: FEV1 &lt; 45 %, RV &gt; 150 %, TLC &gt; 100 %

          -  alpha1 antitrypsin deficiency (&lt; 80 mg/dl), genotype: PiZS, PiZZ, Pi0/0

          -  heterogenous emphysema

        Exclusion Criteria:

          -  homogenous emphysema

          -  significant bronchiectasis

          -  severe concomitant diseases

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Gompelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Gompelmann, MD</last_name>
    <phone>+49(0)62213968087</phone>
    <email>daniela.gompelmann@thoraxklinik-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix JF Herth, MD</last_name>
    <phone>+49(0)62213961200</phone>
    <email>felix.herth@thoraxklinik-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thoraxklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Gompelmann, MD</last_name>
      <phone>+49(0)62213968087</phone>
      <email>daniela.gompelmann@thoraxklinik-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Daniela Gompelmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thoraxklinnik Heidelberg</name_title>
    <organization>Thoraxklinik Heidelberg</organization>
  </responsible_party>
  <keyword>Emphysema</keyword>
  <keyword>alpha1 antitrypsin deficiency</keyword>
  <keyword>endoscopic lung volume reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

